Ppar Delta Inhibition Protects Against Palmitic Acid-Lps Induced Lipidosis And Injury In Cultured Hepatocyte L02 Cell
Yi Li,Chenwei Wang,Jiyuan Lu,Ke Huang,Yu Hang,Junlin Chen,Yan Yang,Bin Liu
DOI: https://doi.org/10.7150/ijms.37677
2019-01-01
International Journal of Medical Sciences
Abstract:Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and its pathogenesis and mechanism are intricate. In the present study, we aimed to evaluate the role of PPAR delta in LPS associated NAFLD and to investigate the signal transduction pathways underlying PPAR delta treatment in vitro. Material and Methods: L02 cells were exposed to palmitic acid (PA) and/or LPS in the absence or presence of PPAR delta inhibition and/or activation. Results: LPS treatment markedly increased lipid deposition, FFA contents, IL-6 and TNF-alpha levels, and cell apoptosis in PA treatment (NAFLD model). PPAR delta inhibition protects L02 cells against LPS-induced lipidosis and injury. Conversely, the result of PPAR delta activation showed the reverse trend. LPS+PA treatment group significantly decreases the relative expression level of IRS-1, PI3K, AKT, phosphorylation of AKT, TLR-4, MyD88, phosphorylation of IKK alpha, NF-kappa B, Bcl-2 and increases the relative expression level of Bax, cleaved caspase 3 and cleaved caspase 8, compared with the cells treated with NAFLD model. PPAR delta inhibition upregulated the related proteins' expression level in insulin resistance and inflammation pathway and downregulated apoptotic relevant proteins. Instead, PPAR delta agonist showed the reverse trend. Conclusion: Our data show that PPAR delta inhibition reduces steatosis, inflammation and apoptosis in LPS-related NAFLD damage, in vitro. PPAR delta may be a potential therapeutic implication for NAFLD.